GLP-1 Receptor Agonist Market

GLP-1 Receptor Agonist Market by Product (Victoza, Ozempic, Trulicity, Bydureon, Saxenda, and Others), and Regions (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2021 – 2028

  • Report ID: HC-770
  • Author: Growth Market Reports
  • Rating: 4.9
  • Total Reviews: 2
  • No. Of Pages: 160
  • Format:
  • Pub. Date: Upcoming
  • Share:

The global GLP-1 receptor agonist market size was valued at USD 11.3 billion in 2019 and is expected expand during the forecast period, 2021–2028. The growth of the market is attributed to the advanced development of GLP-1 receptor agonist and upcoming products for launches.

GLP-1 Receptor Agonist Market Key Takeaways

Incretin mimetics, commonly known as GLP-1 receptor agonist medicines, are a kind of incretin-based drug used to treat type 2 diabetes. The type of medicine is based on function of hormones called incretins, which helps regulate how the pancreas function. GLP-1, a form of incretin, encourages your pancreas to create more insulin after you eat, which helps keep blood glucose levels within acceptable limits. Exanatide, dulaglutide, lixisenatide, and liraglutide are drugs that mimic or replicate the effects of GLP-1 produced by your body. GLP-1's effects last just a few minutes, however GLP-1 receptor agonists can endure for hours or even days. GLP-1 receptor agonists are liquids that are injected under the skin of the abdomen, thigh, or upper arm. You can inject it once or twice daily, or once a week, depending on the drug you are using. GLP-1 receptor agonists can be used on their own or in combination with other diabetic medications.

GLP-1 receptor agonists are particularly efficient at decreasing blood sugar levels after meals and throughout fasting periods. They are unlikely to produce low blood sugar, unlike several type 2 diabetes drugs (hypoglycemia). Some GLP-1 RAs have also been proven to help heart health and kidney function in persons with diabetes, while further study is needed. Treatment with Ozempic, Trulicity, Rybelsus, or Victoza, for example, has been related to a considerable reduction in serious cardiac issues, such as heart attacks, among persons with diabetes and existing heart disease, according to study. Persons who took particular GLP-1 RAs had better renal outcomes than people who took a placebo, according to studies.

Market Trends, Drivers, Restraints, and Opportunities

  • Increasing Prevalence of diabetes and obesity due changing lifestyle and many other factors like genetic mutations is projected to boost the market growth during the forecast period.
  • Growing number of product innovation like new formulations, improved bioavailability, use of combination therapies, and route of administration is expected to drive the market growth during the forecast period.
  • Increasing number of product approval is anticipated to push the market expansion during the forecast period.
  • Increasing geriatric population in developed countries such as US and Japan is expected to drive the market growth in the forecast period.
  • Some products associated with risks and limitations such as renal impairment, pancreatitis, diabetic ketoacidosis is anticipated to hamper the market growth.
  •  Some products not recommended to patients having a medical history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, or serious hypersensitivity to the medication is also expected to restrict the market growth.
  • Adoption of emerging technologies, improvement in healthcare infrastructure and increasing product innovations are projected to offer lucrative opportunities for the market player.

Scope of the Report

The report on the global GLP-1 receptor agonist market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Attributes

Details

Report Title

GLP-1 Receptor Agonist Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast

Base Year

2020

Historic Data

2018–2019

Forecast Period

2021–2028

Segmentation

Product (Victoza, Ozempic, Trulicity, Bydureon, Saxenda, and Others)

Regional Scope

Asia Pacific, North America, Latin America, Europe, and Middle East & Africa

Report Coverage

Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast

Key Players Covered in the Report

Eli Lilly and Company; Sanofi; Novo Nordisk A/S; AstraZeneca


Market Segment Insights

Trulicity segment is expected to constitute a key share of the market
Based on product, the GLP-1 receptor agonist market is segmented into Victoza, Ozempic, Trulicity, Bydureon, Saxenda, and Others. The trulicity segment is expected to constitute a key share of the market during the forecast period owing to increasing demand of product and high penetration of product in developing countries.

On the other hand, the ozempic segment is anticipated to expand at a rapid pace during the forecast period due to various benefits associated with product such as cardiovascular risk reduction, weight loss, and controlled HbA1C levels.

GLP-1 Receptor Agonist Market By Products

North America is anticipated to dominate the market
On the basis of regions, the GLP-1 receptor agonist market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is anticipated to dominate the market at an impressive CAGR during the forecast period. The regional market growth can be attributed to increased application of GLP-1 products and increased R&D expenditure by the government. In the coming years, a well-established biopharmaceutical and pharmaceutical industry is expected to add to the region's dominance.

On the other hand, Asia Pacific is expected to exhibit a rapid growth rate in the coming years owing to increasing prevalence of metabolic disorders such as diabetes and obesity in China and Australia, significant unexplored prospects, and increased R&D spending.

 GLP-1 Receptor Agonist Market By Regions

1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. GLP-1 Receptor Agonist Market Overview
  4.1. Introduction
     4.1.1. Market Taxonomy
     4.1.2. Market Definition
  4.2. Macro-Economic Factors
     4.2.1. Industry Outlook
  4.3. GLP-1 Receptor Agonist Market Dynamics
     4.3.1. Market Drivers
     4.3.2. Market Restraints
     4.3.3. Opportunity
     4.3.4. Market Trends
  4.4. GLP-1 Receptor Agonist Market - Supply Chain
  4.5. Global GLP-1 Receptor Agonist Market Forecast
     4.5.1. GLP-1 Receptor Agonist Market Size (US$ Mn) and Y-o-Y Growth
     4.5.2. GLP-1 Receptor Agonist Market Size (000’ Units) and Y-o-Y Growth
     4.5.3. GLP-1 Receptor Agonist Market Absolute $ Opportunity
5. Global GLP-1 Receptor Agonist Market Analysis and Forecast by Region
  5.1. Market Trends
  5.2. Introduction
     5.2.1. Basis Point Share (BPS) Analysis by Region
     5.2.2. Y-o-Y Growth Projections by Region
  5.3. GLP-1 Receptor Agonist Market Size and Volume Forecast by Region
     5.3.1. North America
     5.3.2. Latin America
     5.3.3. Europe
     5.3.4. Asia Pacific
     5.3.5. Middle East and Africa (MEA)
  5.4. Absolute $ Opportunity Assessment by Region
  5.5. Market Attractiveness/Growth Potential Analysis by Region
  5.6. Global GLP-1 Receptor Agonist Demand Share Forecast, 2019-2026
6. North America GLP-1 Receptor Agonist Market Analysis and Forecast
  6.1. Introduction
     6.1.1. Basis Point Share (BPS) Analysis by Country
     6.1.2. Y-o-Y Growth Projections by Country
  6.2. North America GLP-1 Receptor Agonist Market Size and Volume Forecast by Country
     6.2.1. U.S.
     6.2.2. Canada
  6.3. Absolute $ Opportunity Assessment by Country
  6.4. Market Attractiveness/Growth Potential Analysis
     6.4.1. By Country
     6.4.2. By Product Type
     6.4.3. By Application
  6.5. North America GLP-1 Receptor Agonist Demand Share Forecast, 2019-2026
7. Latin America GLP-1 Receptor Agonist Market Analysis and Forecast
  7.1. Introduction
     7.1.1. Basis Point Share (BPS) Analysis by Country
     7.1.2. Y-o-Y Growth Projections by Country
     7.1.3. Latin America Average Pricing Analysis
  7.2. Latin America GLP-1 Receptor Agonist Market Size and Volume Forecast by Country
      7.2.1. Brazil
      7.2.2. Mexico
      7.2.3. Rest of Latin America
   7.3. Absolute $ Opportunity Assessment by Country
  7.4. Market Attractiveness/Growth Potential Analysis
     7.4.1. By Country
     7.4.2. By Product Type
     7.4.3. By Application
  7.5. Latin America GLP-1 Receptor Agonist Demand Share Forecast, 2019-2026
8. Europe GLP-1 Receptor Agonist Market Analysis and Forecast
  8.1. Introduction
     8.1.1. Basis Point Share (BPS) Analysis by Country
     8.1.2. Y-o-Y Growth Projections by Country
     8.1.3. Europe Average Pricing Analysis
  8.2. Europe GLP-1 Receptor Agonist Market Size and Volume Forecast by Country
     8.2.1. Germany
     8.2.2. France
     8.2.3. Italy
     8.2.4. U.K.
     8.2.5. Spain
     8.2.6. Russia
     8.2.7. Rest of Europe
  8.3. Absolute $ Opportunity Assessment by Country
  8.4. Market Attractiveness/Growth Potential Analysis
     8.4.1. By Country
     8.4.2. By Product Type
     8.4.3. By Application
  8.5. Europe GLP-1 Receptor Agonist Demand Share Forecast, 2019-2026
9. Asia Pacific GLP-1 Receptor Agonist Market Analysis and Forecast
  9.1. Introduction
     9.1.1. Basis Point Share (BPS) Analysis by Country
     9.1.2. Y-o-Y Growth Projections by Country
     9.1.3. Asia Pacific Average Pricing Analysis
  9.2. Asia Pacific GLP-1 Receptor Agonist Market Size and Volume Forecast by Country
     9.2.1. China
     9.2.2. Japan
     9.2.3. South Korea
     9.2.4. India
     9.2.5. Australia
     9.2.6. Rest of Asia Pacific (APAC)
  9.3. Absolute $ Opportunity Assessment by Country
  9.4. Market Attractiveness/Growth Potential Analysis
     9.4.1. By Country
     9.4.2. By Product Type
     9.4.3. By Application
  9.5. Asia Pacific GLP-1 Receptor Agonist Demand Share Forecast, 2019-2026
10. Middle East & Africa GLP-1 Receptor Agonist Market Analysis and Forecast
  10.1. Introduction
     10.1.1. Basis Point Share (BPS) Analysis by Country
     10.1.2. Y-o-Y Growth Projections by Country
     10.1.3. Middle East & Africa Average Pricing Analysis
  10.2. Middle East & Africa GLP-1 Receptor Agonist Market Size and Volume Forecast by Country
     10.2.1. Saudi Arabia
     10.2.2. South Africa
     10.2.3. UAE
     10.2.4. Rest of Middle East & Africa (MEA)
  10.3. Absolute $ Opportunity Assessment by Country
  10.4. Market Attractiveness/Growth Potential Analysis
     10.4.1. By Country
     10.4.2. By Product Type
     10.4.3. By Application
  10.5. Middle East & Africa GLP-1 Receptor Agonist Demand Share Forecast, 2019-2026
11. Competition Landscape
  11.1. Global GLP-1 Receptor Agonist Market: Market Share Analysis
  11.2. GLP-1 Receptor Agonist Distributors and Customers
  11.3. GLP-1 Receptor Agonist Market: Competitive Dashboard
  11.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
     11.4.1. Eli Lilly and Company
     11.4.2. Sanofi
     11.4.3. Novo Nordisk A/S
     11.4.4. AstraZeneca
Segments Covered in the Report
The global GLP-1 receptor agonist market has been segmented on the basis of

Product
  • Victoza
  • Ozempic
  • Trulicity
  • Bydureon
  • Saxenda
  • Others
Regions
  • Asia Pacific
  • North America
  • Latin America
  • Europe
  • Middle East & Africa
Key Players
  • Eli Lilly and Company
  • Sanofi
  • Novo Nordisk A/S
  • AstraZeneca

Key players competing in the GLP-1 receptor agonist market are Eli Lilly and Company; Sanofi; Novo Nordisk A/S; AstraZeneca.

Some of the business strategies adopted by the key players include as mergers, acquisitions, partnerships, collaborations, capacity expansion, and product launches to increase/enhance their market shares. For example, in January 2020, Sanofi announced the acquisition of Synthorx, Inc. This acquisition will aid the firm in expanding its product line and generating revenue in the next years, owing to the extended genetic alphabet platform technology.

 GLP-1 Receptor Agonist Market By Key Players

Buy Report